These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25405759)

  • 1. MDM4 overexpressed in acute myeloid leukemia patients with complex karyotype and wild-type TP53.
    Li L; Tan Y; Chen X; Xu Z; Yang S; Ren F; Guo H; Wang X; Chen Y; Li G; Wang H
    PLoS One; 2014; 9(11):e113088. PubMed ID: 25405759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.
    Rücker FG; Russ AC; Cocciardi S; Kett H; Schlenk RF; Botzenhardt U; Langer C; Krauter J; Fröhling S; Schlegelberger B; Ganser A; Lichter P; Zenz T; Döhner H; Döhner K; Bullinger L
    Leukemia; 2013 Feb; 27(2):353-61. PubMed ID: 22810507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.
    Tan BX; Khoo KH; Lim TM; Lane DP
    Oncotarget; 2014 Feb; 5(4):933-43. PubMed ID: 24659749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
    Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and
    Dannheim KC; Pozdnyakova O; Dal Cin P; Weinberg OK
    J Clin Pathol; 2018 Dec; 71(12):1051-1059. PubMed ID: 30171088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin-specific protease 2a stabilizes MDM4 and facilitates the p53-mediated intrinsic apoptotic pathway in glioblastoma.
    Wang CL; Wang JY; Liu ZY; Ma XM; Wang XW; Jin H; Zhang XP; Fu D; Hou LJ; Lu YC
    Carcinogenesis; 2014 Jul; 35(7):1500-9. PubMed ID: 24445145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.
    Xu N; Lai YY; Chen WM; Jiang H; Wang Y; Wang X; Zhao XS; Huang XJ; Jiang Q; Qin YZ
    Int J Lab Hematol; 2022 Oct; 44(5):892-899. PubMed ID: 35505580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia.
    Yoshida S; Onozawa M; Miyashita N; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Hirabayashi S; Mori A; Hidaka D; Minauchi K; Shigematsu A; Hashiguchi J; Igarashi T; Kakinoki Y; Tsutsumi Y; Ibata M; Kobayashi H; Haseyama Y; Fujimoto K; Ishihara T; Sakai H; Ota S; Kondo T; Teshima T
    Int J Hematol; 2023 Apr; 117(4):544-552. PubMed ID: 36572814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
    Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
    Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition.
    Moison C; Lavallée VP; Thiollier C; Lehnertz B; Boivin I; Mayotte N; Gareau Y; Fréchette M; Blouin-Chagnon V; Corneau S; Lavallée S; Lemieux S; Marinier A; Hébert J; Sauvageau G
    Blood Adv; 2019 Feb; 3(4):552-563. PubMed ID: 30782614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.
    Leung GMK; Zhang C; Ng NKL; Yang N; Lam SSY; Au CH; Chan TL; Ma ESK; Tsui SP; Ip HW; So JCC; Ng MHL; Cheng KCK; Wong KF; Siu LLP; Yip SF; Lin SY; Lau JSM; Luk TH; Lee HKK; Lau CK; Kho B; Kwong YL; Leung AYH
    Am J Hematol; 2019 Jun; 94(6):650-657. PubMed ID: 30900772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
    Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
    Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
    Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
    Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells.
    Samudio IJ; Duvvuri S; Clise-Dwyer K; Watt JC; Mak D; Kantarjian H; Yang D; Ruvolo V; Borthakur G
    Leuk Lymphoma; 2010 May; 51(5):911-919. PubMed ID: 20423286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
    Rücker FG; Schlenk RF; Bullinger L; Kayser S; Teleanu V; Kett H; Habdank M; Kugler CM; Holzmann K; Gaidzik VI; Paschka P; Held G; von Lilienfeld-Toal M; Lübbert M; Fröhling S; Zenz T; Krauter J; Schlegelberger B; Ganser A; Lichter P; Döhner K; Döhner H
    Blood; 2012 Mar; 119(9):2114-21. PubMed ID: 22186996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
    Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
    Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.
    Irish JM; Anensen N; Hovland R; Skavland J; Børresen-Dale AL; Bruserud O; Nolan GP; Gjertsen BT
    Blood; 2007 Mar; 109(6):2589-96. PubMed ID: 17105820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
    Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
    Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
    Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.